Pharmacokinetics, Pharmacodynamics, and Safety of MEDI4212, an Anti-IgE Monoclonal Antibody, in Subjects with Atopy: A Phase I Study

Conclusions The increased potency of MEDI4212 may be of clinical interest for individuals with high-diagnostic IgE levels where more extensive IgE suppression is required for clinical response. However, the modest duration of free IgE suppression below the target concentration noted with MEDI4212 in this study suggests limited potential for dosing schedule advantages over omalizumab. Funding MedImmune. Trial registration ClinicalTrials.gov identifier, NCT01544348.

http://link.springer.com/10.1007/s12325-016-0287-8

Source: Advances in Therapy - February 3, 2016 Category: Drugs & Pharmacology Source Type: research